Imunon Inc

$2.64
(as of Jun 3, 9:33 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Imunon Inc

Stock Price
$2.64
Ticker Symbol
IMNN
Exchange
NASDAQ

Industry Information for Imunon Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Imunon Inc

Website
https://imunon.com
Country
USA
Full Time Employees
25

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Fundamentals for Imunon Inc

Market Capitalization
$44,029,668
EBITDA
$-18,029,744
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.38
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
17,541,700
Percent Owned by Insiders
1.52%
Percent Owned by Institutions
2.35%
52-Week High
52-Week Low

Technical Indicators for Imunon Inc

50-Day Moving Average
200-Day Moving Average
RSI
60.35
ATR
0.44

Analyst Ratings for Imunon Inc

Strong Buy
2
Buy
1
Hold
1
Sell
0
Strong Sell
0

News About Imunon Inc

Jun 3, 2025, 8:05 AM EST
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response See more.
Jun 2, 2025, 8:05 AM EST
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology See more.
May 28, 2025, 11:55 PM EST
Imunon, Inc. See more.
May 28, 2025, 5:16 PM EST
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants See more.